Is TB-500 Legal in Australia?

The Short Answer

TB-500 (a synthetic fragment related to thymosin beta-4) is not approved by the Therapeutic Goods Administration (TGA), it is not listed on the Australian Register of Therapeutic Goods (ARTG), and it is treated as a research-use-only laboratory compound. It cannot lawfully be supplied to the public for personal use in Australia. Both thymosin beta-4 and TB-500 are captured by the Poisons Standard as prescription-only (Schedule 4) substances, and there is no finished product carrying TGA evaluation for safety, quality or efficacy.

In practice this means TB-500 sits in the same regulatory bracket as other unapproved and scheduled peptides: it has a defined place in the Poisons Standard, but no approved therapeutic product behind it. The remainder of this guide expands on what each of those terms means and where TB-500 fits so the picture is clear and accurate.

What TB-500 Actually Is

TB-500 is a short synthetic peptide. In neutral structural terms, it is a laboratory-made, acetylated fragment derived from the actin-binding region of thymosin beta-4, a naturally occurring protein found in many tissues. TB-500 is not the full-length protein. It is a defined partial sequence produced synthetically for laboratory settings.

Because TB-500 and full-length thymosin beta-4 are frequently discussed together, it is worth keeping the distinction precise. Thymosin beta-4 is the complete, naturally occurring molecule. TB-500 is a shorter synthetic fragment designed to carry part of that sequence. Regulators generally treat the two together when they appear in the Poisons Standard and on anti-doping lists.

• TB-500: a synthetic, acetylated peptide fragment based on part of the thymosin beta-4 sequence.
• Thymosin beta-4: the full-length naturally occurring protein.
• Both are named together in Australian scheduling and in anti-doping frameworks.

TB-500 (thymosin beta-4) research overview

TGA Status: Not Approved, Not on the ARTG

The ARTG is the public register of therapeutic goods that have been evaluated and approved for supply in Australia. There is no TB-500 or thymosin beta-4 finished product on the ARTG. That absence matters: it means no TB-500 product has passed TGA evaluation for safety, quality or efficacy, and no sponsor holds an approval to market it to the Australian public.

The TGA has publicly raised concern about the importation and supply of unapproved peptides, noting that such products have not been assessed by the regulator. Importantly, labelling a product as experimental or for research only does not change its legal status for supply, possession or use. The research-use framing describes the intended laboratory context of the material, not a loophole that makes public supply lawful.

Where TB-500 Sits in the Poisons Standard

The Poisons Standard (the SUSMP) classifies substances into schedules that determine how they may be accessed. Thymosin beta-4 and TB-500 are captured as Schedule 4 (prescription-only) substances, and they also appear in Appendix D, which lists substances subject to additional possession and supply controls.

The practical consequence is straightforward. A Schedule 4 listing means a substance is restricted to supply on the authority of a suitably qualified health practitioner. Combined with the absence of any approved product, this leaves no lawful route for a member of the public to buy TB-500 for personal use from a general retailer.

• Schedule 4: prescription-only status under the Poisons Standard.
• Appendix D: additional possession and supply controls.
• No approved product means no standard consumer supply pathway exists.

WADA and Sport: Banned at All Times

Thymosin beta-4 and TB-500 are prohibited under the World Anti-Doping Agency (WADA) Prohibited List. They fall within class S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) and are banned at all times, meaning both in competition and out of competition.

For anyone bound by anti-doping rules, this is significant. TB-500 and its related derivatives are treated as non-specified substances in this category, and anti-doping bodies have sanctioned athletes for their use. The ban reflects the regulatory presumption applied to growth-factor-type substances in this class, independent of whether a performance effect has been demonstrated in humans.

Is BPC-157 legal in Australia?

Research Stage: Investigational and Limited Human Data

TB-500 is best described as investigational. The available scientific literature is largely pre-clinical, drawing on cell and animal models, with limited human data. Thymosin beta-4 has been examined in pre-clinical research in areas related to cell migration and tissue biology, and TB-500 appears in that same literature as a synthetic fragment used in laboratory settings.

It is important not to overstate this. Pre-clinical interest does not equal an approved therapeutic use, and the absence of an ARTG entry reflects that no TB-500 product has been evaluated and approved for human use in Australia. Describing what research has looked at is a neutral scientific statement, not a claim about any outcome for an individual.

Can You Buy TB-500 in Australia?

Because there is no approved product and the substance is prescription-only under the Poisons Standard, there is no ordinary consumer purchase pathway for TB-500 in Australia. Where TB-500 is offered, it is offered strictly as a research-use-only laboratory compound, not as a product for human or animal use.

This research-use framing is not a marketing flourish. It defines the only context in which such materials are handled: controlled laboratory settings, by those equipped for that work. It does not authorise supply to the general public, and it carries no suggestion of personal benefit. If you are evaluating a supplier, the governance questions that matter are provenance and verification, which is where third-party testing becomes relevant.

• No ARTG product means no standard retail consumer route.
• Any legitimate handling is research-use-only, not for human or animal use.
• Documentation and independent verification are the markers of a serious laboratory supplier.

Third-party tested peptides in Australia

Key Takeaways

Pulling the regulatory picture together, TB-500 occupies a clearly defined but restrictive position in Australia. It is not approved, not registered, and tightly scheduled, and it is banned in sport at all times.

• TB-500 is not TGA-approved and not on the ARTG.
• Thymosin beta-4 and TB-500 are Schedule 4 (prescription-only) and appear in Appendix D of the Poisons Standard.
• There is no lawful general-public supply route for personal use.
• WADA prohibits thymosin beta-4 and TB-500 under class S2, banned at all times.
• The evidence base is largely pre-clinical with limited human data.
• Research-use-only framing describes a laboratory context, not a consumer product.